Dr. Reddy’s Laboratories is creating a branded generics platform in North America and expanding biologics play in Russia and emerging marketsNew Delhi: Dr. Reddy’s Laboratories Ltd expects complex generics, proprietary products, including creation of branded generics platform in the US, to be the main drivers of its growth going forward. Dr. Reddy’s Laboratories had posted a consolidated net income from sales and services of Rs.15,470.8 crore for 2015-16. “Our growth, going forward, will be driven by the attractive pipeline of complex generics as well as our new proprietary products,” Dr Reddy’s Laboratories chairman K. Satish Reddy said in a message in the company’s latest annual report. During fiscal 2016, the company’s revenues from North America for generics grew 19% to Rs.7,540 crore. The company will leverage these across the markets we operate in, together with increasing our OTC (over-the-counter) portfolio, he added.

Source: Mint July 17, 2016 16:52 UTC